Jaime Avecillas, MD
Pulmonary Disease · Miami, FLNPI 1366409245
Payments from drug & device makers
Across 438 payments — averaging $3736.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$1.6M
- Boehringer Ingelheim$63K
- Inspire Medical Systems, Inc.$1K
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$912
- Mallinckrodt Hospital Products Inc.$854
- plus $3K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 79 | $1,566,271 |
| Boehringer Ingelheim | 110 | $63,051 |
| Inspire Medical Systems, Inc. | 13 | $1,316 |
| Actelion Pharmaceuticals US, Inc. | 33 | $1,217 |
| GSK | 55 | $912 |
| Mallinckrodt Hospital Products Inc. | 26 | $854 |
| Insmed, Inc. | 29 | $679 |
| AstraZeneca | 29 | $559 |
| Harmony Biosciences LLC | 9 | $418 |
| Verona Pharma, Inc. | 11 | $228 |
| Regeneron Healthcare Solutions, Inc. | 6 | $193 |
| Bayer | 8 | $184 |
| Sanofi | 6 | $144 |
| United Therapeutics Corporation | 4 | $88 |
| Mylan Specialty L.p. | 2 | $69 |
| Teva Pharmaceuticals USA, Inc. | 2 | $58 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Baxter Healthcare | 2 | $40 |
| Merck | 2 | $38 |
| Resmed Corp | 2 | $38 |
| Inogen, Inc. | 1 | $34 |
| Viatris Specialty LLC | 1 | $25 |
| Nabriva Therapeutics, PLC | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
How this compares
$1,636,580 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Miami
- James KrainsonMiami$11.7M
- Lourdes BoschMiami$4.2M
- Manuel SuarezMiami$3M
- Eduardo VasquezMiami$1.9M
- Manuel Hernandez-AbrilMiami$1.9M
- Trishul SiddharthanMiami$1.2M
- Shirin ShafazandMiami$969K
- Yoel BritoMiami$802K
- Maria Tupayachi OrtizMiami$716K
- Michael HernandezMiami$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.